研究单位：[1]Sichuan Cancer Hospital and Research Institute[2]Chia Tai Tianqing Pharmaceutical Group Co.,Ltd.[3]Zigong fourth people's hospital Zigong,China[4]People's hospital of guangan city Guangan,China[5]The affiliated hospital of southwest medical university Luzhou,China[6]Nanchong central hospital Nanchong,China[7]Neijing second people's hospital Neijiang,China[8]Suning central hospital Suning,China[9]Zigong first people's hospital Zigong,China
研究目的：
This study is conducted to explore the safety and efficacy of anlotinib,a tyrosine kinase inhibitors of Vascular Endothelial Growth Factor Receptor 2（VEGFR）、FGFR（Fibroblast Growth Factor Receptor）,Platelet-derived growth factor Receptor（PDGFR） and c-kit,vs docetaxel in advanced Non-squamous Non-small cell lung cancer harbouring wild-type epidermal growth factor receptor (EGFR) .
